Study: The Number of New Dermatology Drugs Approved by the FDA Is on the Rise
The number of new dermatologic drug approvals by the U.S. Food and Drug Administration (FDA) increased between 2012 and 2022 compared with prior decades, according to a research letter in JAMA Dermatology. Nearly half of these drugs were considered first in class or first in indication, and several were deemed clinically useful or to have high […]
TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology
Sudo Biosciences Raises $116M Series B Financing to Advance TYK2 Therapeutics Programs Into the Clinic Sudo Biosciences raised $116 million Series B financing to advance two investigational TYK2 candidates into the clinic in 2024. Sudo is developing a potential first-in-class topical TYK2 inhibitor for psoriasis and other immune-mediated dermatologic diseases. In addition, Sudo’s CNS program is […]
New and Emerging Systemic Therapies for Alopecia Areata
The alopecia areata treatment landscape continues to make important advancements. In part 4 of this educational series, Dr. George Han discusses the pathogenesis of alopecia areata, potential clinical targets, and new and emerging systemic therapies for alopecia areata. About this Series Evidence-based advancements and therapeutic options continue to emerge in the treatment of alopecia areata. […]
Long-term Use of Steroid Creams Linked to Osteoporosis, Fractures
Higher doses of topical corticosteroids may increase risk of the brittle bone disease osteoporosis and associated fractures, according to research in the Journal of the European Academy of Dermatology and Venereology. Investigators selected 129,682 osteoporosis cases and 34,999 major osteoporotic fracture (MOF) cases and matched them with 518,728 and 139,996 controls (without osteoporosis or MOF) by […]